The use of U-500 regular insulin in the management of patients with obesity and insulin resistance

Diabetes Obes Metab. 2013 Oct;15(10):882-7. doi: 10.1111/dom.12094. Epub 2013 Apr 4.

Abstract

The rise in prevalence of obesity and diabetes has created a challenge in managing increasing numbers of patients who require high doses of insulin. This article reviews the published literature on the properties of U-500 insulin and its use in clinical practice. U-500 insulin is likely to have a longer time to peak effect and a longer duration of action than similar doses of U-100 insulin. Evidence for its use in clinical practice rests on retrospective case series, which suggests that the use of U-500 insulin either by multiple daily injections or a continuous subcutaneous insulin infusion is effective in improving glycaemic control. To prevent insulin dosing and administration errors, great care must be taken in providing staff and patient education, and in developing policies for the management of patients on U-500 insulin who are admitted to hospital.

Keywords: U-500 insulin; insulin resistance; obesity; type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Blood Glucose / drug effects*
  • Blood Glucose / metabolism
  • Cost-Benefit Analysis
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Dose-Response Relationship, Drug
  • Evidence-Based Medicine
  • Female
  • Glycated Hemoglobin / drug effects*
  • Glycated Hemoglobin / metabolism
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Injections, Subcutaneous
  • Insulin Infusion Systems
  • Insulin Resistance*
  • Insulin, Regular, Human / therapeutic use*
  • Male
  • Obesity / blood
  • Obesity / drug therapy*
  • Obesity / epidemiology
  • Patient Education as Topic
  • Treatment Outcome

Substances

  • Blood Glucose
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin, Regular, Human
  • hemoglobin A1c protein, human